VisionGate, Inc., an in vitro diagnostics company that is developing a revolutionary, non-invasive test for the early detection of lung cancer and other applications, today announced that data on sensitivity and specificity of its LuCED lung cancer detection test will be presented at the American Society of Clinical Oncology’s (ASCO) 50th annual conference at McCormick Place in Chicago. ASCO runs from May 30 to June 2.
Help employers find you! Check out all the jobs and post your resume.
